US biotech Biogen (Nasdaq: BIIB) today posted full-year and fourth-quarter financial results for 2018. Full year total revenues were $13.5 billion, a 10% increase versus the prior year.
Full year GAAP net income and diluted earnings per share (EPS) attributable to Biogen Inc. were $4.4 billion and $21.58, respectively, compared to $2.5 billion and $11.92, respectively, in the prior year.
For the fourth-quarter, total revenue increased 6.6% to $3.53 billion, exceeding consensus estimates of $3.40 billion. Net income attributable to Biogen was $946.8 million, or $4.73 per share, for the three months, compared with a net loss of $297.4 million, or $1.40 per share, a year earlier. Adjusted EPS was $6.99 a share, beating the FactSet consensus of $6.73 a share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze